Wave life sciences reports first quarter 2025 financial results and provides business update

Dosing complete in the first two cohorts of inlight trial in obesity of wve-007 (inhbe sirna), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2h 2025 dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in restoraation-2 clinical trial of wve-006 in individuals with pizz aatd; data from the complete 200 mg multidose and single dose cohorts expected in 3q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 delivered positive data from forward-53 clinical trial of wve-n531 in exon 53 amenable dmd including statistically significant and clinically meaningful improvement in ttr, substantial improvements in muscle health; nda submission for accelerated approval with monthly dosing planned for 2026 ind submission expected 2h 2025 for potentially registrational wve-003 phase 2/3 study in hd with caudate atrophy as a primary endpoint cash and cash equivalents of $243.1 million as of march 31, 2025, with runway expected into 2027 investor conference call and webcast at 8:30 a.m. et today cambridge, mass.
WVE Ratings Summary
WVE Quant Ranking